Skip to main content
IMRX logo

Immuneering Corporation

IMRXNASDAQHealthcareBiotechnology

$3.59Today:- (-)1Y −34.77%

As of Oct 16, 2026 close

Market cap
$235.50M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.41$8.48
Volume (live)
-
Avg. volume (3M)
761.36K

Immuneering (IMRX) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Immuneering posted a net loss of $56.02M, compared with a net loss of $61.04M a year earlier.

Immuneering Income Statement Analysis

Values in millions USD

Scroll to see more
Immuneering Corporation income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.000.000.000.322.082.311.92
Cost of Revenue0.700.000.000.161.151.281.22
Gross Profit-0.700.000.000.160.931.030.70
Operating Expenses
Research & Development42.0547.9641.6236.2726.5415.004.28
Selling, General & Administrative17.3016.0816.7615.618.273.112.71
Operating Expenses58.6864.0758.4151.9034.8118.116.99
Operating Income-59.38-64.07-58.41-51.75-33.89-17.08-6.29
Other Income/Expense
Interest Income3.042.593.611.010.170.040.06
Interest Expense0.000.000.000.000.000.000.35
Other Income/Expense3.350.444.940.22-0.13-0.04-1.42
Income
Income Before Tax-56.02-61.04-53.47-50.51-33.84-17.12-7.71
Income Tax Expense0.000.000.000.00-0.31-0.080.00
Net Income-56.02-61.04-53.47-50.51-33.54-17.04-7.71
Net Income - Continuous Operations-56.02-61.04-53.47-50.51-33.54-17.04-7.71
Net Income - Discontinued Operations-------
EBITDA-55.33-63.69-58.06-51.47-33.73-17.00-7.34
EBIT-59.38-64.07-58.41-51.75-33.89-17.08-
Depreciation & Amortization0.700.030.350.030.160.080.02
Earnings Per Share
Basic EPS-1.00-2.00-2.00-2.00-2.00-1.00-1.00
Diluted EPS-1.00-2.00-2.00-2.00-2.00-1.00-1.00
Basic Shares Outstanding44.0129.9828.4226.3913.6113.5113.51
Diluted Shares Outstanding44.0129.9828.4226.3913.6113.5113.51

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Immuneering Financial Statements

Is Immuneering profitable?

No. Immuneering reported a net loss of $56.02M in fiscal 2025. In fiscal 2024 it lost $61.04M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition